Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Giovannoni G, Airas L, Bove R, Cutter GR, Czarnecki M, Drulovic J, Hobart J, Kuhle J, Montalban X, Selmaj KW, Tur C, Wolinsky JS, Baldinotti A, Bonati U, Craveiro L, Giacobino C, Manfrini M, Schneble HM, Stevenson P, Wang Q, Yang K, Oh J, ORATORIO-HAND study group

Open source

DOI: 10.1016/s0140-6736(26)00617-3
Published: 2026 May 30
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00617-3,
  title = {Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.},
  author = {Giovannoni G and Airas L and Bove R and Cutter GR and Czarnecki M and Drulovic J and Hobart J and Kuhle J and Montalban X and Selmaj KW and Tur C and Wolinsky JS and Baldinotti A and Bonati U and Craveiro L and Giacobino C and Manfrini M and Schneble HM and Stevenson P and Wang Q and Yang K and Oh J and ORATORIO-HAND study group},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00617-3},
  url = {https://doi.org/10.1016/s0140-6736(26)00617-3}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
AU  - Giovannoni G
AU  - Airas L
AU  - Bove R
AU  - Cutter GR
AU  - Czarnecki M
AU  - Drulovic J
AU  - Hobart J
AU  - Kuhle J
AU  - Montalban X
AU  - Selmaj KW
AU  - Tur C
AU  - Wolinsky JS
AU  - Baldinotti A
AU  - Bonati U
AU  - Craveiro L
AU  - Giacobino C
AU  - Manfrini M
AU  - Schneble HM
AU  - Stevenson P
AU  - Wang Q
AU  - Yang K
AU  - Oh J
AU  - ORATORIO-HAND study group
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00617-3
UR  - https://doi.org/10.1016/s0140-6736(26)00617-3
ER  -

APA

G, G., L, A., R, B., GR, C., M, C., J, D., J, H., J, K., X, M., KW, S., C, T., JS, W., A, B., U, B., L, C., C, G., M, M., HM, S., P, S., Q, W., K, Y., J, O., & group, O. S. (2026). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00617-3

Source records

pubmed · retrieved 2026-09-26T22:47:35.703Z